• 2025 Legislative Session: CHAIN helped lead the fight to put patients first in the massive but little-known federal prescription drug discount program. Hospitals siphon hundreds of millions of dollars in 340B discounts that should go to lowering the cost of drugs. Instead, the money flows into a black hole, with no accountability or transparency.  The 340B reform initiative fell short in Colorado’s 2025 Legislative Session, but we are far from finished.

• The Colorado Prescription Drug Affordability Board (PDAB) continues its 4-year record of wasting taxpayer dollars, ignoring patient concerns and providing ZERO in prescription savings to consumers.

  CHAIN joins with other business, patient, consumer and industry organizations in opposing the current path of the PDAB and pushing for an entirely new direction that focuses on saving PATIENTS money, NOT insurers.

• 2025 Legislative Session: CHAIN launched a first-of-its kind digital communications campaign to organize everyday consumers in the fight for fairer healthcare. Holding drug middlemen accountable and lowering out of pocket costs were key objectives. Over 500 Connecticut consumers signed up to help pass legislation that ultimately was tabled by the state assembly.

• In Connecticut’s 2026 Legislative Session, CHAIN launched a full-scale communications and consumer advocacy campaign to help defeat SB 494 - a bill that would have expanded the federal 340B drug discount program without meaningful transparency, accountability, or proof that savings were reaching patients.

  Through a widespread digital campaign, we educated CT residents about the risks of SB 494 and provided clear tools for them to take action.

  By combining public education, digital advocacy, direct constituent engagement, and patient storytelling, CHAIN helped ensure that Connecticut lawmakers heard directly from the people most affected by high drug prices and unaffordable care.

  SB 494 was ultimately defeated - a major victory for Connecticut patients!

CHAIN is working in Massachusetts to stop harmful 340B policies that would expand a broken federal drug discount program without ensuring patients benefit.

The 340B program was created to help low-income and vulnerable patients access affordable care. But too often, hospitals buy drugs at steep discounts, charge patients and insurers far more, and keep the difference — without proving those savings are reaching the people the program was meant to help.

In Massachusetts, this lack of accountability is especially concerning as families face high drug costs, medical debt, and reduced access to care. Across the state, 340B hospitals have closed or suspended maternity services in vulnerable communities, forcing expectant moms and families to travel farther for care.

CHAIN is educating consumers, elevating patient voices, and urging Massachusetts lawmakers to reject 340B expansion and instead focus on transparency, medical debt relief, and federal reforms that ensure savings reach patients — not hospital executives.

In 2025, CHAIN ran a comprehensive media campaign in MA to stop harmful 340b expansion legislation - and was successful.